| The emerging role for type 5 phosphodiesterase inhibition in heart failure. | |
| | |
MedLine Citation:
|
PMID: 16914104 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with heart failure (HF) due to left ventricular (LV) systolic dysfunction have abnormal endothelium-dependent, nitric oxide-cyclic guanosine monophosphate-mediated vasodilation in the pulmonary and skeletal muscle vasculature. Therefore, inhibition of type 5 phosphodiesterase (PDE5), the principle enzyme responsible for cyclic guanosine monophosphate catabolism in the lungs and skeletal muscle, has been targeted in an effort to counteract vasoconstriction that contributes to increased right and LV afterload in HF. The efficacy of PDE5 inhibition in the treatment of pulmonary arterial hypertension has led to the investigation of its potential utility in the treatment of HF patients with secondary pulmonary hypertension. Moreover, recent preclinical studies suggest direct myocardial effects of PDE5 inhibition that may counteract beta-adrenergic, hypertrophic, and pro-apoptotic signaling, three critical pathways in the development of LV dysfunction. This review outlines both the underlying rationale and the results of initial studies of the therapeutic effects of PDE5 inhibition in HF. |
| | |
Authors:
|
Gregory D Lewis; Marc J Semigran |
Related Documents
:
|
3988674 - Determinants of cardiac augmentation by elevations in intrathoracic pressure. 15637114 - Regional myocardial work by strain doppler echocardiography and lv pressure: a new meth... 20545994 - New, simple echocardiographic indexes for the estimation of filling pressure in patient... 7054574 - Left ventricular diastolic suction as a mechanism of ventricular filling. 16296704 - Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension... 8279374 - Circulatory and catecholamine changes during head-up tilt testing in neurocardiogenic (... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current heart failure reports Volume: 3 ISSN: 1546-9530 ISO Abbreviation: Curr Heart Fail Rep Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-08-17 Completed Date: 2006-12-22 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101196487 Medline TA: Curr Heart Fail Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 123-8 Citation Subset: IM |
Affiliation:
|
Cardiology Division, Bigelow 800, MassachusettsGeneral Hospital, 55 Fruit St., Boston, MA 02114, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
3',5'-Cyclic-GMP Phosphodiesterases
/
antagonists & inhibitors* Cyclic Nucleotide Phosphodiesterases, Type 5 Exercise Tolerance / drug effects Heart / drug effects Heart Failure / drug therapy* Humans Phosphodiesterase Inhibitors / pharmacology, therapeutic use* Piperazines / pharmacology, therapeutic use Purines Sulfones Vasodilation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Sulfones; 139755-83-2/sildenafil; EC 3.1.4.35/3',5'-Cyclic-GMP Phosphodiesterases; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5; EC 3.1.4.35/PDE5A protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thyroid hormone and heart failure.
Next Document: Management of acute pulmonary edema in the emergency department.